Aspartate transaminase to platelet ratio index in hepatitis C virus and Schistosomiasis coinfection

Aspartate aminotransferase-to-platelet ratio index for fibrosis and cirrhosis prediction in chronic hepatitis C patients.

In chronic hepatitis C (CHC), liver biopsy is the gold standard method for assessing liver histology, however it is invasive and can have complications. Non-invasive markers have been proposed and aspartate aminotransferase (AST)-to-platelet ratio index (APRI) has been shown as an easy and inexpensive marker of liver fibrosis. This study evaluated the diagnostic performance of APRI for signific...

Noninvasive assessment of liver fibrosis with aspartate transaminase to platelet ratio index (APRI)

Adler M. Noninvasive assessment of liver fibrosis with aspartate transaminase to platelet ratio index (APRI). In chronic liver diseases, the management of patients must include a determination of the stage of fibrosis (to select specific therapies), a prognosis, the prevention of complications, and the surveillance of the disease. Over the past several years, significant progress has been made ...

aspartate transaminase to platelet ratio index (apri) to assess liver fibrosis in patients with chronic liver disease

Aspartate aminotransferase to platelet ratio index and blood platelet count are good markers for fibrosis evaluation in schistosomiasis mansoni.

The assessment of periportal fibrosis is of major importance in determining strategies, prognosis and risk for complications in schistosomiasis mansoni . For the last 2 decades, abdominal ultrasound has been used as the gold standard for the evaluation of liver fibrosis in schistosomiasis mansoni , because hepatic biopsy has been shown to have low sensitivity in diagnosing advanced schistosomia...

Aspartate transaminase to platelet ratio index (APRI) to assess liver fibrosis in patients with chronic liver disease

In patients with chronic liver disease (CLD), liver biopsy is currently an indispensable reference method to assess inflammatory activity and fibrosis stage and thus to estimate prognosis and guide management decisions in such patients. Given that the presence of advanced fibrosis is a predictor of nonresponse, the decision (1) to begin antiviral therapy in cases of chronic viral hepatitis is h...